Space reserved for health professionals
This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.
mAbXmise determines the plasma concentration of monoclonal antibodies prescribed as single or combination therapies at selected time points. Its unique technology is based on mass spectrometry and allows multiplex measurement (several mAbs at once) with high analytical performances. The kit is designed to be easy-to-use and allows optimal reliability and accuracy using LC/MS technology. Healthcare professionals can then use the information to personalize treatment and manage patient care [1]
Therapeutic drug monitoring consists of measuring the plasma concentration of a drug, so as to adjust the dosing and maintain its target plasma concentration.
Since the 2000s, monitoring of therapeutic antibodies has begun to emerge in the management of inflammatory diseases and oncology, with immunological methods.
mAbXmise uses a different approach. It lies on mass spectrometry, a particularly sensitive and above all extremely specific technology. The technology allows the therapeutic antibody in the sample to be measured very accurately.
We believe the onset of mAbXmise technology will dramatically change the way biologics are monitored in the future.
Current treatment regimens are still either single-dose or calculated on the basis of patient weight, whereas there is increasing evidence of inter-patient variability due to several factors such as age, gender, pathological state and others.
With mAbXmise, we hope we can facilitate the adoption of this practice in the hospital, to allow individualized medicine by personalizing the frequency of administration, compensate for inter-individual variability and reducing treatment costs.[1]
[1] Marin, C.; et al. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals 2021, 14, 796. https://doi.org/10.3390/ph14080796
mAbXmise kits are in vitro diagnostic medical devices intended for healthcare professionals. These are monoclonal antibody quantification kits: see the specific instructions for more information
The range developed by Promise Proteomics includes 7 products and cover 6 therapeutic areas :
oncology, inflammation, transplantation, rheumatology, hemophilia and hematology
INFLAMMATION : Infliximab; Adalimumab; Obinutuzumab; Secukinumab; Tocilizumab; Ustekinumab; Vedolizumab
ONCOLOGY : Bevacizumab; Rituximab; Cetuximab; Trastuzumab; Nivolumab; Pembrolizumab; Ipilimumab
TRANSPLANTATION & RHEUMATOLOGY : Abatacept; Belatacept
HEMOPHILIA : Emicizumab
HEMATOLOGY : Eculizumab; Ravulizumab
ANTI-DRUG ANTIBODIES INFLAMMATION : ANTI-Infliximab; ANTI-Adalimumab
INCLUDED IN EACH KIT :
-96 well plate coated with stable labelled mAbs (internal standards)
-6 Calibrators
-2 Quality Controls
-Suited buffers and solutions
-Specific consumables
-Protease
From the patient’s blood sample to the monitoring of therapeutic antibodies,
mAbXmise diagnostic kits are:
sample preparation with mAbXmise labelled
internal standards added to blood sample
quantitative analysis
using mass spectrometry,
measuring simultaneously
several therapeutic mAbs
measurement of therapeutic mabs
with 100% accuracy and
specificity according to
the peptide signature
Promise Proteomics was created in 2010 as a spin-off of CEA Grenoble (France). This medtech company is currently wholly owned by the Aguettant group and is directed by Dr Eric Rougemond.
Since 2013, Chief Scientific Officer of Promise, Dorothee Lebert, has led ambitious and collaborative R&D programs which have allowed to develop the technology, on which the diagnostic kits for personalized medical applications are based.
Capitalizing on its unique know-how in the production of internal standards for protein assays and its recognized expertise in mass spectrometry-based quantification methods, Promise Proteomics is placing its skills at the service of healthcare professionals through its mAbXmise kits.
Innovation, Development, Industrialization, Production capacities, Market Acess & Regulatory affairs, Quality are the expertises gathered by the company.
patents
patents
articles on Therapeutic
Drug Monitoring
articles on Therapeutic
Drug Monitoring
years of expertise
in proteomics
years of expertise
in proteomics
TDM projects in
our pipeline
TDM projects in
our pipeline
KEY REFERENCES> Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals. 2021 |
> Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods. Bioanalysis 2022 |
AWARDS> Awardee of the Proof-of-concept program for ambitious R&D programs in public-private partnership, addressing a medical need in Oncology (2017) |
> Semifinalist of AACC’s disruptive technology award session rewarding the next innovative testing solution that will transform patient care (2018) |
The related patents numbers are :US11543416, US11053303, US11630111, EP3165928, EP3165922, and EP3457139 |
Pilot clinical study at Lyon University Hospital (HCL, France) |
|
|
Launched in 2017, MADMAS study aims at developing a dosing method to monitor plasma levels of nivolumab, pembrolizumab and ipilimumab and to draw a exposure-response correlation in patients with lung cancer and melanoma. |
 |
Quality Affairs & Regulatory affairs
Promise proteomics kits are now CE IVD marked.
Promise proteomics is also ISO9001 / ISO13485 certified and will then seek approval by the Food and Drug Administration (FDA 510K) for the US market.
Keep up with our latest news
Promise Proteomics
7, parvis Louis Néel • BHT 52 A • CS 20050
38040 Grenoble Cedex 9 • FRANCE
PHONE: +33 4 38 02 36 50